TSHA (Taysha Gene Therapies) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSHA Taysha Gene Therapies Inc TSHA
33 GF Score
Price $5.02
GF Value $0.53
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Taysha Gene Therapies Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Taysha Gene Therapies Quality Rank Related Terms

TSHA
33GF Score
Taysha Gene Therapies Inc TSHA
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Taysha Gene Therapies (TSHA) Overvalued in 2026?

Based on GuruFocus' analysis, Taysha Gene Therapies stock appears to be overvalued. The current stock price of $5.02 is trading 847.2% above its estimated GF Value™ of $0.53. GuruFocus considers Taysha Gene Therapies to be Significantly Overvalued.

Key valuation signals for TSHA:

  • Quality Rank:
  • GF Value™: $0.53 vs. price of $5.02 (847.2% above fair value)
  • GF Score™: 33/100 with 2 warning signs

No single metric tells the full story. See the TSHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Taysha Gene Therapies Business Description

Address 3000 Pegasus Park Drive, Suite 1430, Dallas, TX, USA, 75247
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
33GF Score

Get the complete analysis for TSHA

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.02
Price
$0.53
GF Value